BioOrbit, a pioneering in-space drug manufacturing company, has successfully secured £9.8 million in a landmark seed funding round. This investment, co-led by LocalGlobe and Breega, is set to accelerate the company's mission to produce pharmaceutical drugs in orbit at an industrial scale. The funding represents the largest seed round globally for in-space manufacturing, signaling strong confidence in this emerging sector.
Revolutionizing Drug Delivery from Space
A significant portion of the world's highest-grossing drugs, approximately 70 percent, currently require intravenous administration in clinical settings. BioOrbit aims to fundamentally change this by reformulating these treatments into subcutaneous, self-injectable formats for patients. This innovation could shift critical care, including cancer therapies, from the hospital environment directly to a patient's home.
The company leverages the unique microgravity environment of low-Earth orbit to overcome key manufacturing challenges found on Earth. This process facilitates the growth of highly ordered, perfect crystals from protein-based drugs, which is not achievable terrestrially. These superior crystals reduce the viscosity of high-concentration antibody therapies, enabling the development of patient-friendly injectable treatments.
The Technology Enabling Orbital Production
Central to BioOrbit's strategy is its proprietary technology, a compact and autonomous manufacturing unit named BOX. Roughly the size of a microwave, this modular system is designed for deployment in microgravity to manage the crystallization process. It effectively transitions drug crystallization from a singular experiment into a scalable, industry-ready production line in space.
Dr. Katie King, founder and CEO of BioOrbit, emphasized the company's focus on achieving industrial scale where others have not succeeded. She stated that their process enables the creation of superior crystals, unlocking drug formulations previously impossible to create on Earth. This development marks a paradigm shift for the pharmaceutical industry and the future of orbital manufacturing.
Landmark Investment and Strategic Expansion
The £9.8 million financing round stands as the world's largest seed investment for an in-space manufacturing venture. The round was co-led by prominent venture capital firms LocalGlobe and Breega, with significant participation from Auxxo, Seedcamp, and Type One. This substantial backing underscores the immense market potential investors see in BioOrbit's innovative approach to pharmaceuticals.
This new capital will fuel BioOrbit's transition from scientific breakthroughs to contracted pharmaceutical programs and industrial deployment. To lead this expansion, the company has appointed Dr. Molly Mulligan as President and Dr. Ken Savin as Chief Science Officer. Their combined expertise in space-based pharma commercialization and drug development will be instrumental in driving the company's next phase of growth.
Industry and Government Endorsement
Investors have expressed strong confidence in the company's vision to transform healthcare by turning space into pharmaceutical infrastructure. Julia Hawkins of LocalGlobe highlighted the potential to shift cancer treatment to the home, rewriting how medicines are made and delivered. Similarly, Matthieu Vallin of Breega praised the world-class team for harnessing the unique properties of space to advance medicine.
The initiative has also garnered widespread support from key figures in the UK's space and government sectors. Lord David Willetts, Chair of the UK Space Agency, praised the startup's innovation, while Space Minister Liz Lloyd highlighted it as a compelling example of UK leadership. This broad endorsement reinforces the strategic importance of in-orbit manufacturing for both economic growth and patient outcomes.
BioOrbit's record-breaking seed round marks a pivotal moment for the future of pharmaceutical manufacturing and the commercial space industry. With substantial financial backing and a clear technological path, the company is poised to transform drug delivery for millions of patients. This venture not only advances cancer treatment but also solidifies the UK's position at the forefront of the global space economy.